|
11. |
Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis |
|
Melanoma Research,
Volume 12,
Issue 1,
2002,
Page 77-82
G. Hofbauer,
R. Böni,
D. Simmen,
D. Mihic,
F. Nestle,
G. Burg,
R. Dummer,
Preview
|
PDF (785KB)
|
|
摘要:
Nasal mucosa melanoma is a rare entity that may occur together with nasal melanosis. The histological and immunological features and loss of heterozygosity analysis of such lesions have not been reported to date. In the study presented here short-term cell cultures were established from the patient's melanoma and subsequent relapses. Histology, immunohistochemistry, reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay, human leukocyte antigen analysis, microdissection with subsequent polymerase chain reaction for analysis of loss of heterozygosity were used to characterize the tumour and other cells. Melanoma of the nasal cavity was found, with a surrounding proliferation of atypical melanocytes corresponding to nasal melanosis. Immunoreactivity was found for S-100, gp100, tyrosinase and MelanA protein. Loss of heterozygosity for a p16-flanking marker was found in the tumour and the melanotic cells. Short-term cell cultures expressed tyrosinase and MUC18 at the mRNA level and intercellular adhesion molecule-1 (ICAM-1) and interleukin-12 receptor at the protein level. This is the first time short-term cell cultures have been established and analysed from such a tumour. Melanoma-associated antigens were identified within the tumour. The melanoma and the melanotic cells showed loss of heterozygosity for the p16 gene, which is implicated in melanoma development. This points to a common origin in tumorigenesis. Pathways of tumour escape, such as expression of CD54 and interleukin-10, were observed. The clinical, immunological and molecular features suggest that nasal melanosis should be followed closely.
ISSN:0960-8931
出版商:OVID
年代:2002
数据来源: OVID
|
12. |
Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients: a pilot trial |
|
Melanoma Research,
Volume 12,
Issue 1,
2002,
Page 83-90
S. Mahabir,
D. Coit,
L. Liebes,
M. Brady,
J. Lewis,
G. Roush,
M. Nestle,
D. Fry,
M. Berwick,
Preview
|
PDF (187KB)
|
|
摘要:
We evaluated the effects of vitamin E (dl-α-tocopherol) on mutagen sensitivity levels in a randomized placebo-controlled pilot trial. In brief, a dietary supplement of 1000 mg/day vitamin E or a placebo was randomly administered for 3 months to melanoma outpatients clinically free of the disease. Plasma vitamin E and mutagen sensitivity levels were measured at baseline and at the end of the trial after 3 months. At baseline, we found no significant differences in plasma vitamin E and mutagen sensitivity levels between the two groups. We also measured dietary intake at baseline and found dietary vitamin E to be a poor predictor of plasma levels of vitamin E. After 3 months of supplementation, we found that plasma levels of α-tocopherol increased significantly (P= 0.0005) in the vitamin E compared to the placebo group. We also found a non-significant, but consistent decrease in plasma γ-tocopherol concentrations in the vitamin E supplemented compared to the placebo group. We did not find any significant difference between the vitamin E and placebo groups in mutagen sensitivity levels either at baseline or after 3 months of supplementation. We conclude that short term vitamin E supplementation, although it causes increased blood levels of α-tocopherol, does not provide protection against bleomycin-induced chromosome damage.
ISSN:0960-8931
出版商:OVID
年代:2002
数据来源: OVID
|
13. |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study |
|
Melanoma Research,
Volume 12,
Issue 1,
2002,
Page 91-98
S. Jelić,
N. Babovic,
V. Kovcin,
N. Milicevic,
N. Milanovic,
I. Popov,
D. Radosavljevic,
Preview
|
PDF (176KB)
|
|
摘要:
The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose–effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones. A total of 219 patients with metastatic cutaneous melanoma were included in this study; 196 of them were evaluable for activity. The patients were randomized into four treatment arms: arm A (standard dose dacarbazine arm), vincristine 1.4 mg/m2on day 1, carmustine (BCNU) 60 mg/m2on day 1, and dacarbazine 300 mg/m2per 24 h on days 2–5; arm B (high-dose dacarbazine arm), vincristine and BCNU as in arm A and dacarbazine 600 mg/m2per 24 h on days 2–5; arm C (`aggressive’ regimen without dacarbazine), vindesine 3 mg/m2on day 1, bleomycin 7 mg/m2per 24 h on days 1–4, and cisplatin 30 mg/m2per 24 h on days 5–8; arm D (`non-aggressive’ regimen without dacarbazine), BCNU 100 mg/m2on day 1 and procarbazine 90 mg/m2per 24 h on days 1–10. The four arms were well balanced with regard to patient- and disease-related characteristics. On an intend-to-treat basis, the response rate was 11 out of 49 (22%) in arm A, nine out of 47 (19%) in arm B, 16 out of 63 (25%) in arm C and nine out of 60 (15%) in arm D. There was a large overlap between the 95% confidence intervals and no significant differences in the response rates between the four arms. Median survival in the four treatment arms was 4, 5, 6 and 4 months, respectively, again with no significant differences. Median survival for responders (8, 11, 10 and 13 months, respectively) in all four arms was significantly longer than in non-responders (4, 3, 5 and 4 months, respectively). Arms A, B and C were significantly more toxic compared with arm D, which was for all practical purposes devoid of toxicities. The efficacy of all four regimens thus appeared comparable both in terms of response rate and survival. Responders in all four arms achieved a survival benefit. There does not seem to be a dose–effect relationship for dacarbazine in metastatic melanoma. Chemotherapy from arm D, might be well suited for ‘fragile’ or elderly patients due to the lack of toxicity.
ISSN:0960-8931
出版商:OVID
年代:2002
数据来源: OVID
|
|